Clearant Achieves Another Key Milestone in Direct Distribution of Tissue Implants to Surgeons, Hospitals and Clinics: Company Announces the Launch of Clearant Sterile Implants Through Direct Sales Force.

LOS ANGELES -- Clearant Executes Direct Distribution Strategy to Meet Rising Demand for Sterile Tissue Transplant Materials

Clearant, Inc. (OTCBB:CLRI) today announced that, for the first time, it has made Clearant Sterile Implants(R) for cervical spinal allograft surgery available through its direct sales force. Clearant's direct sales team is now marketing the tissues treated with the Clearant Process(R) to surgeons, hospitals and clinics in six U.S. markets. Currently, the top fifteen markets in the U.S. represent in excess of $200 million in bone implant sales. The top 30-50 surgeons in these markets perform approximately 80% of the procedures, allowing the Company to employ a highly targeted marketing effort.

"In our studies conducted at UCLA and presented at the annual meeting of the North American Spinal Surgery Society last year, we demonstrated that the Clearant Process can sterilize bone while not affecting the osteoinductive and osteoconductive nature of the allograft," wrote Jeffrey C. Wang, M.D. Chief, Orthopedic Spine Service, Associate Professor of Orthopedics and Neurosurgery, U.C.L.A. Comprehensive Spine Center, U.C.L.A. School of Medicine.

"We are pleased to have the support of many orthopedic surgeons, including Dr. Wang. The direct support of key opinion leader surgeons will help our direct sales force educate the larger orthopedic surgeon community about the benefits of the Clearant Process sterile implants; in my experience, the support of key opinion leader surgeons will prove to be instrumental in ramping up the adoption of the Clearant Process sterile bone implants we are launching today," said Clearant Chief Executive Officer Alain Delongchamp. "To-date, we are very pleased that the response from experienced spinal and orthopedic sales representatives is extremely positive; in fact, we are ahead of our hiring plan. We hired two more experienced orthopedic sales representatives in the last week; this brings our total of dedicated spinal sales representatives to 6."

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of pathogens in biological products while maintaining the functionality of the underlying protein. The Company began distribution directly to surgeons, hospitals and clinics Clearant Process sterile implants in June 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with a Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com: http://www.clearant.com/.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, efficacy of the technology, success of our direct distribution, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.